New drug UP-818-CC passes first safety check in healthy volunteers
NCT ID NCT07355621
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested the safety and tolerability of a new drug, UP-818-CC, in 73 healthy Chinese volunteers. Participants received either a single dose or multiple daily doses of the drug or a placebo. The main goal was to check for side effects and measure how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- UP-818-CC injection
- What this could lead to
- If successful, this could pave the way for future studies testing UP-818-CC as a potential treatment for an unspecified condition.
- What could go wrong
- This is an early Phase 1 safety study in healthy people, so it cannot show whether the drug works for any disease. Side effects may emerge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer reveals the Body's journey of an experimental drug
- Can music lessons rewire Teens' social media habits?
- Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Sound waves as medicine: ultrasound may tame inflammation without drugs
- Broader pneumonia shield: new vaccine tested in children